Amgen Inc. (AMGN) has been a focal point for investors and stock positions across multiple firms. Notably, companies like
Coastline Trust Co and
HM Payson & Co. have increased their stake while others like
OneDigital Investment Advisors LLC and
Truist Financial Corp have decreased their holdings. A notable aspect is the release of
full results from Part 1 of the Phase 2 study of MariTide, which has generated interest and coverage. Despite some share sales by entities like Bank of New York Mellon Corp, the company continues to outperform the broader market, making it a
strong value stock. The
MariTide tolerability update has been reaffirmed by Piper Sandler, while some stocks have been moved, with Amgen falling 5.8% following
Novo Nordisk's weight loss drug trial. However, it remains a firm choice for long-term growth. Recent developments also include the
positive gastric cancer trial results with Zai Lab and a new phase 3 trial for a weight loss drug amid mixed investor sentiments.
Amgen AMGN News Analytics from Mon, 24 Mar 2025 07:00:00 GMT to Sat, 05 Jul 2025 20:09:03 GMT -
Rating 7
- Innovation 3
- Information 8
- Rumor -3
